Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
25884 | 222 | 31.0 | 38% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1294 | 8163 | FOOD AND DRUG LAW JOURNAL//GENERIC SUBSTITUTION//DIRECT TO CONSUMER ADVERTISING |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | PROGRAM LIFE SCI ETH POLICY | Address | 5 | 60% | 3% | 6 |
2 | MCLAUGHLIN ROTMAN GLOBAL HLTH | Address | 4 | 19% | 9% | 20 |
3 | ESRC INNOGEN | Address | 3 | 20% | 5% | 12 |
4 | BIOTECH AND PHARMA INDUSTRIES | Author keyword | 2 | 67% | 1% | 2 |
5 | INNOGEN | Address | 2 | 29% | 2% | 5 |
6 | ESRC SOCIAL ECON INNOVAT GENOM | Address | 1 | 33% | 1% | 2 |
7 | 4WD TOURISM | Author keyword | 1 | 50% | 0% | 1 |
8 | BIO OBJECTS | Author keyword | 1 | 50% | 0% | 1 |
9 | BIOCOLONIALITY | Author keyword | 1 | 50% | 0% | 1 |
10 | CHAGAS DISEASE DIAGNOSIS | Author keyword | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | BIOTECH AND PHARMA INDUSTRIES | 2 | 67% | 1% | 2 | Search BIOTECH+AND+PHARMA+INDUSTRIES | Search BIOTECH+AND+PHARMA+INDUSTRIES |
2 | 4WD TOURISM | 1 | 50% | 0% | 1 | Search 4WD+TOURISM | Search 4WD+TOURISM |
3 | BIO OBJECTS | 1 | 50% | 0% | 1 | Search BIO+OBJECTS | Search BIO+OBJECTS |
4 | BIOCOLONIALITY | 1 | 50% | 0% | 1 | Search BIOCOLONIALITY | Search BIOCOLONIALITY |
5 | CHAGAS DISEASE DIAGNOSIS | 1 | 50% | 0% | 1 | Search CHAGAS+DISEASE++DIAGNOSIS | Search CHAGAS+DISEASE++DIAGNOSIS |
6 | CORPORATE PRACTICE | 1 | 50% | 0% | 1 | Search CORPORATE+PRACTICE | Search CORPORATE+PRACTICE |
7 | EVOLUTION AND GROWTH | 1 | 50% | 0% | 1 | Search EVOLUTION+AND+GROWTH | Search EVOLUTION+AND+GROWTH |
8 | GENOMIC SOVEREIGNTY | 1 | 50% | 0% | 1 | Search GENOMIC+SOVEREIGNTY | Search GENOMIC+SOVEREIGNTY |
9 | HEALTH BIOTECHNOLOGY | 1 | 50% | 0% | 1 | Search HEALTH+BIOTECHNOLOGY | Search HEALTH+BIOTECHNOLOGY |
10 | HEALTH INNOVATION SYSTEM | 1 | 50% | 0% | 1 | Search HEALTH+INNOVATION+SYSTEM | Search HEALTH+INNOVATION+SYSTEM |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | HEALTH BIOTECH SECTOR | 6 | 80% | 2% | 4 |
2 | LIFE SCIENCE INNOVATION | 6 | 100% | 2% | 4 |
3 | BIOTECH SECTOR | 3 | 100% | 1% | 3 |
4 | CHINESE HEALTH | 2 | 50% | 1% | 3 |
5 | HEALTH BIOTECH | 2 | 50% | 1% | 3 |
6 | BIO OBJECTS | 1 | 38% | 1% | 3 |
7 | BIOTECH | 1 | 18% | 2% | 4 |
8 | CONTRIBUTION SPANS | 1 | 50% | 0% | 1 |
9 | EBV VECTOR | 1 | 50% | 0% | 1 |
10 | PRODUCT DEVELOPMENT PARTNERSHIPS | 1 | 50% | 0% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
A special report on India's biotech scenario: Advancement in biopharmaceutical and health care sectors | 2010 | 5 | 7 | 100% |
Great expectations: The state of biotechnology research and development in South Africa | 2008 | 7 | 1 | 100% |
From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries | 2011 | 2 | 14 | 57% |
Development of health biotechnology in developing countries: Can private-sector players be the prime movers? | 2012 | 3 | 7 | 43% |
Indian entrepreneurship in biotechnology comes of age | 2012 | 0 | 3 | 67% |
Opportunities and barriers to establishing a cell therapy programme in South Africa | 2013 | 1 | 6 | 33% |
JAPANS GROWING PHARMACEUTICAL-INDUSTRY - A THREAT TO THE UNITED-STATES | 1989 | 0 | 2 | 100% |
Digitization and Its Discontents: Future Shock in Predictive Oncology | 2010 | 2 | 8 | 13% |
Africa: Continent of genome contrasts with implications for biomedical research and health | 2012 | 8 | 42 | 7% |
Biotechnology in South Africa | 2006 | 9 | 10 | 10% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PROGRAM LIFE SCI ETH POLICY | 5 | 60% | 2.7% | 6 |
2 | MCLAUGHLIN ROTMAN GLOBAL HLTH | 4 | 19% | 9.0% | 20 |
3 | ESRC INNOGEN | 3 | 20% | 5.4% | 12 |
4 | INNOGEN | 2 | 29% | 2.3% | 5 |
5 | ESRC SOCIAL ECON INNOVAT GENOM | 1 | 33% | 0.9% | 2 |
6 | DEV POLICY PRACTICE UNIT | 1 | 50% | 0.5% | 1 |
7 | ESRC INNOGEN DEV POLICY PRACTICE | 1 | 50% | 0.5% | 1 |
8 | GENOME EVOLUT INFORMAT | 1 | 50% | 0.5% | 1 |
9 | MAESTRA CIENCIAS | 1 | 50% | 0.5% | 1 |
10 | NISTADS | 1 | 50% | 0.5% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000145311 | BIOCHEMICAL ENGINEERING SCIENCE//IF I CLERSE//UVB |
2 | 0.0000131110 | STEM CELL TOURISM//PROGRAM STEM CELLS SOC//UK STEM CELL BANK |
3 | 0.0000084008 | EGLETES VISCOSA//AUXEMMA ONCOCALYX//ONCOCALYXONE A |
4 | 0.0000079673 | COMPULSORY LICENSING//ACCESS TO MEDICINES//DOHA DECLARATION |
5 | 0.0000076575 | ORPHAN DRUGS//RARE DISEASES//OFF ORPHAN PROD DEV |
6 | 0.0000071543 | DEVELOPMENT OF SOCIETIES//INDIGENOUS ACCREDITATION//MT ROMANCE |
7 | 0.0000064898 | NATIONAL IMMUNIZATION TECHNICAL ADVISORY GROUP NITAG//IMMUNIZATION FINANCING//PROVAC INITIAT |
8 | 0.0000064325 | COUNTRYSIDE COMMUNITY//BADGER VACCINATION//PLANT AND ANIMAL HEALTH |
9 | 0.0000060729 | LATECOMER FIRMS//TECHNOLOGICAL CAPABILITIES//TECHNOLOGICAL CAPABILITY ACCUMULATION PATHS |
10 | 0.0000059909 | RIVER VALUES//COMPARAT INT DEV INTERDISCIPLINARY ARTS SCI PRO//ERGONOMICS IMPACT |